Industry: Healthcare Region: US Deal Price: $1 million Deal Method: Equity financing
Introduction to the
The American biotech company is looking to raise $43 million in its final round of funding for an IPO on nasdaq. A biopharmaceutical technology company specializing in immune system T cells.
The main research is t-cell, the treatment of cancer virus, improve the immune system research. Focus on the development and manufacturing of fresh immune cells as the active ingredient of immunotherapy products.
We have business cooperation with Tsinghua University, have several technical cooperation, and have patent rights in China. The licensed invention includes a method for processing living cell compositions in a nutrient-free buffer. Is a method for in vitro processing a biologic pharmaceutical composition containing living cells for use in immunotherapy.